Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.
Clinical overview of the seizure risk of dalfampridine.
Gilenya prescribing information
Laquinimod - New Promising Treatment for Multiple Sclerosis
Editorial for JNV issue on PML.
Amyloid precursor protein at node of Ranvier modulates nodal formation.
22nd Meeting of European Neurological Society
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Function and distribution of three types of rectifying channel in rat spinal root myelinated axons.
Patients with migraine do not have MRI-visible cortical lesions.
Arzerra receives approval in Japan
Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
First NW patient to receive OHSU/VAMC-invented MS drug
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
Development of the Brief Inventory of Perceived Stress.
Neuromyelitis optica spectrum disorder: 2-deoxy-2-[(18)f]fluoro-d-glucose positron emission tomography findings.
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.

Pages